BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Queensland Health
Chubb
Medtronic
Boehringer Ingelheim
Express Scripts
Chinese Patent Office
US Department of Justice
Fuji
Moodys

Generated: January 16, 2018

DrugPatentWatch Database Preview

XOLEGEL Drug Profile

« Back to Dashboard

Which patents cover Xolegel, and what generic alternatives are available?

Xolegel is a drug marketed by Aqua Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has twenty-eight patent family members in fifteen countries.

The generic ingredient in XOLEGEL is ketoconazole. There are fifteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the ketoconazole profile page.
Summary for XOLEGEL
Drug patent expirations by year for XOLEGEL

US Patents and Regulatory Information for XOLEGEL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aqua Pharms XOLEGEL ketoconazole GEL;TOPICAL 021946-001 Jul 28, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Aqua Pharms XOLEGEL ketoconazole GEL;TOPICAL 021946-001 Jul 28, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Aqua Pharms XOLEGEL ketoconazole GEL;TOPICAL 021946-001 Jul 28, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for XOLEGEL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,238,683 Anhydrous topical skin preparations ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for XOLEGEL

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Cipla
McKinsey
Harvard Business School
AstraZeneca
Cerilliant
Fuji
Fish and Richardson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot